| (210) | Number of the EPO application | 17761332 |
| (220) | Filing date of the EPO application | 2017.08.09 |
| (80) | EPO patent specification publication (B) | EPB nr. 41/2020, 2020.10.07 |
| (110) | EPO patent number | 3500564 |
| (11) | Number of the document | MD 3500564 T2 |
| (21) | Number of the application | e 2019 0711 |
| (71) | Name(s) of applicant(s), code of the country | Pfizer Inc., US; |
| (72) | Name(s) of inventor(s), code of the country | BOEHM Markus, US;
CABRAL Shawn, US;
DOWLING Matthew S., US;
FUTATSUGI Kentaro, US;
HUARD Kim, US;
LEE Esther Cheng Yin, US;
LI Qifang, US;
LONDREGAN Allyn T., US;
POLIVKOVA Jana, US;
PRICE David A., US; |
| (73) | Name(s) of owner(s), code of the country | PFIZER INC., US; |
| (54) | Title of the invention | Diacylglycerol acyltransferase 2 inhibitors |
| (13) | Kind-of-document code | T2 |
| (51) | International Patent Classification | C07D 401/14 (2006.01.01); A61K 31/506 (2006.01.01); A61P 3/00 (2006.01.01) |
| (19) | Country | US |
| (41) | Date of publication of the application | 2019.07.31 |
| (49) | Date of publication of the translation of the validated European patent specification | 2020.12.31 |
| (30) | Priority | 201662377137 P, 2016.08.19, US |
| (74) | Patent attorney | (Procedură) LAZICOV Tatiana, str. A. Pușkin nr. 33, ap. 73, MD-2012, Chișinau, Republica Moldova |
| (86) | International application | PCT/IB2017/054862, 2017.08.09 |
| (87) | International publication | WO 2018/033832, 2018.02.22 |